- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc stock price live, this page displays NASDAQ SNDX stock exchange data. View the SNDX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Syndax Pharmaceuticals Inc real time stock price chart below.
What Is the Syndax Pharmaceuticals Inc Stock Price Today?
The Syndax Pharmaceuticals Inc stock price today is 20.77.
What Is the Stock Symbol for Syndax Pharmaceuticals Inc?
The stock symbol for Syndax Pharmaceuticals Inc is "SNDX."
What Stock Exchange Does Syndax Pharmaceuticals Inc Trade On?
Syndax Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Syndax Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Syndax Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SNDX quote. (ISIN: US87164F1057)
What Is the Syndax Pharmaceuticals Inc Stock Price Today?
The Syndax Pharmaceuticals Inc stock price today is 20.77.
What Is the Stock Symbol for Syndax Pharmaceuticals Inc?
The stock symbol for Syndax Pharmaceuticals Inc is "SNDX."
What Stock Exchange Does Syndax Pharmaceuticals Inc Trade On?
Syndax Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Syndax Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Syndax Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SNDX quote. (ISIN: US87164F1057)
20.77
+0.85(+4.27%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.01
20.88
52 wk Range
12.99
25.59
SNDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.0120.88
52 wk Range
12.9925.59
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SNDX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
37.91
Upside
+82.52%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 37.91
(+82.52% Upside)
Syndax Pharmaceuticals Inc SWOT Analysis
Revuforj's Impact | Explore Syndax's breakthrough in AML treatment with Revuforj, surpassing sales expectations and rapidly penetrating key market accounts |
Clinical Triumphs | Delve into Syndax's promising clinical data for venetoclax/azacitidine combination therapy, positioning the company as a formidable player in AML treatment |
Pipeline Potential | Discover Syndax's diverse pipeline, including Niktimvo for GVHD, showcasing the company's commitment to expanding its oncology portfolio |
Market Valuation | Analyst price targets range from $19 to $56 per share, with a consensus rating of 1.15, indicating strong bullish sentiment despite profitability challenges |
Syndax Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- Syndax missed Q2 2026 estimates with $0.55 loss per share vs. $0.48 expected; revenue of $73M fell short of $79.8M consensus by 8.52%
- Revenue surged 92% YoY to $72.8M; Revuforj generated $54.7M, Niktimvo $18.1M collaboration revenue, both annualizing above $200M each
- Company ended quarter with $575M cash after issuing $250M convertible notes at 2.25%; maintained 2026 R&D/SG&A guidance at ~$400M
- CEO projects Revuforj peak revenue exceeding $2B in U.S. alone; expects H2 2026 catalysts including IPF data and myelofibrosis study start
- Shares fell 4.63% to $18.35 after-hours despite strong fundamentals; management attributed lower new patient starts to temporary anomaly
Last Updated: 2026-08-04, 06:00 p/m
Read Full TranscriptEarnings
Latest Release
Aug 04, 2026
EPS / Forecast
-0.55 / -0.48
Revenue / Forecast
73M / 79.8M
Compare SNDX to Peers and Sector
Metrics to compare | SNDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSNDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.3x | −1.7x | −0.3x | |
PEG Ratio | −0.23 | −0.14 | 0.00 | |
Price/Book | 121.9x | 2.6x | 2.6x | |
Price / LTM Sales | 7.3x | 7.3x | 3.1x | |
Upside (Analyst Target) | 85.7% | 83.2% | 50.4% | |
Fair Value Upside | Unlock | 17.9% | 6.4% | Unlock |
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Syndax Pharmaceuticals (SNDX) Stock Price Today?
The Syndax Pharmaceuticals stock price today is 20.77 USD.
What Stock Exchange Does Syndax Pharmaceuticals Trade On?
Syndax Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Syndax Pharmaceuticals?
The stock symbol for Syndax Pharmaceuticals is "SNDX."
What Is the Syndax Pharmaceuticals Market Cap?
As of today, Syndax Pharmaceuticals market cap is 1.86B USD.
What Is Syndax Pharmaceuticals's Earnings Per Share (TTM)?
The Syndax Pharmaceuticals EPS (TTM) is -2.51.
When Is the Next Syndax Pharmaceuticals Earnings Date?
Syndax Pharmaceuticals will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is SNDX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Syndax Pharmaceuticals Stock Split?
Syndax Pharmaceuticals has split 0 times.
How Many Employees Does Syndax Pharmaceuticals Have?
Syndax Pharmaceuticals has 298 employees.
What is the current trading status of Syndax Pharmaceuticals (SNDX)?
As of Aug 19, 2026, Syndax Pharmaceuticals (SNDX) is trading at a price of 20.77 USD, with a previous close of 19.92 USD. The stock has fluctuated within a day range of 20.01 USD to 20.88 USD, while its 52-week range spans from 12.99 USD to 25.59 USD.
What Is Syndax Pharmaceuticals (SNDX) Price Target According to Analysts?
The average 12-month price target for Syndax Pharmaceuticals is 37.91 USD, with a high estimate of 57 USD and a low estimate of 26 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +82.52% Upside potential.
What Is the SNDX Premarket Price?
SNDX's last pre-market stock price is 20.01 USD. The pre-market share volume is 4,200.00, and the stock has decreased by 0.10, or 0.48%.
What Is the SNDX After Hours Price?
SNDX's last after hours stock price is 19.34 USD, the stock has decreased by -0.58, or -2.91%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.